Caitlin's Master's thesis focused on age-related changes in mesenchymal stem cells using a murine model. She is a current member of the Histochemical Society and the International Society for Stem Cell Research.
John spent his graduate studies looking into exocystosis, and his post-doctoral years studying the process of synaptogenesis. He has used a variety of western blotting, immnuofluorescence and ELISA based applications to study these processes.
Jeremy joined the Neurobiology faculty at UAB in 2014, where his lab investigates the neurobiology of reward- related memory systems in the brain and the role of these circuits in motivated behaviours. His research integrates molecular, physiological, behavioral, genetic and epigenetic tools to understand how experience alters epigenetic states in the brain- with specific interest in the role of non-coding RNAs within this process.
His ultimate goal is to manipulate epigenetic or transcriptional patterns within selected neuronal populations to achieve therapeutic outcomes from the brain diseases. His work is supported by research grants from the National Institute on Drug Abuse, the Pittman Scholars Program, and by the Evelyn McKnight Brain Institute.
Dr Lee is currently a principal investigator at the Cambridge Stem Cell Institute, at the University of Cambridge, UK. Together with her group, she focuses on understanding the cellular behavior and regulatory networks of adult stem and niche cells in homeostasis and regeneration.
Since 2006, Cristina has been led the Cell Death Regulation Group at the Division of Molecular Oncology in the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain. The main interest of her team is to understand why and how cells die when deprived of nutrients in the context of cancer and brain ischemia.
Andrew completed his postdoctoral training at St. Jude Children's Research Hospital in Memphis, TN, and in 2012 he joined the University of Washington's Department of Immunology as an Assistant Professor. Dr Oberst's research focuses on understanding the pathways of programmed cell death, and how different forms of cell death are perceived by the immune system.
In 1999, Dr Prendergast became Senior Director of Cancer Research at DuPont Pharmaceuticals. In 2002, his research groups moved from Wistar and DuPont to the Lankenau Institute for Medical Research outside Philadelphia, where he is currently Professor, President and CEO. In 2010, Dr Prendergast was appointed Editor-in-Chief of Cancer Research, the AACR flagship journal, and the most highly cited journal in the field.
Dr Alejandra Solache joined Abcam in 2013 as Head Reagents Product Development and Manufacturing globally. She is responsible for managing the output of the Abcam Cambridge, Hangzhou and Bristol laboratories, specifically the New Product Development, Core reagents and R&D. She also plays a key role in developing Abcam’s innovation strategy.
Prior to joining Abcam she held various positions at EMD-Millipore, latterly as R&D Director, leading the Antibody and Assay Development teams. She gained expertise in Immunology, cell signaling and cell biology through postdoctoral fellowships at UCSF and the Trudeau Institute.
Jean Paul serves as a Scientific Advisor of the Dean of Medical School NUS, Singapore, and in a number of other Institutions worldwide. He was until June 2015, Professor and Head of the Biochemistry Department, School of Medicine at NUS. He has also served a joint appointment as Research Director at IMCB A*STAR Singapore, and Senior Principal Investigator at the Cancer Science Institute at NUS.
Jean Paul is credited as the first to propose that EMT control invasion and dissemination while the reverse process, MET, is required for the development of clinically detectable metastases in carcinoma. His current research's focus is to unravel the mechanisms of invasion and metastasis of carcinoma cells, while his seminal contributions to bladder carcinoma studies have led to the discovery of the molecular mechanisms underlying the formation of superficial or invasive tumors. Currently, his research is focusing on oncogenomics and the creation of functional approaches to characterize bladder, lung breast, and ovarian carcinoma progression- with the ultimate goal to apply EMT-based therapeutic approaches in the near future.
He is an EMBO and Academia Europea member. He has been made Chevalier (Knight) in the order the Legion d'Honneur , the highest distinction in France, in 2009.
As an innovator in reagents and tools, our purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, we offer highly validated biological binders and assays to address ...See more See less
The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
For bugs, spam, technical support or questions please call +1-714-463-4673 or
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events